IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67

Ciclopirox Olamine: A Comprehensive Pharmacological, Clinical and Commercial Monograph

Kumar S. Yadav[1], Rushikesh S. Ubale[2], Rutuja A. Adagale[3], Onkar N. Dhole[4]
Students, JBVP`S Vidya Niketan Collage of Pharmacy, Lakhewadi[1,2,3]
Assistant Professor, JBVP`S Vidya Niketan Collage of Pharmacy, Lakhewadi, India[4]

Abstract: *Dermatophytosis is a common superficial fungal infection involving keratinized tissues such as the skin, hair and nails. Over the past two decades, it has become an increasingly significant public health concern, particularly in tropical and subtropical regions like India, where warm climates and overcrowded living conditions promote fungal spread. The growing incidence of chronic, recurrent, and recalcitrant dermatophytosis has been strongly associated with the irrational use of topical corticosteroid–antifungal combinations and the rising resistance to conventional antifungal agents.*
CiclopiroxOlamine (CPO), a synthetic hydroxypyridone derivative, offers a unique pharmacological profile compared to traditional antifungal classes. Unlike azoles and allylamines—which primarily act by inhibiting ergosterol synthesis—CPO exerts a multi-targeted mechanism by chelating metal ions essential for fungal cellular metabolism. This action disrupts multiple biochemical pathways simultaneously, ultimately inhibiting fungal growth and survival.
Clinical studies, retrospective analyses and published reports consistently demonstrate the effectiveness and safety of topical CiclopiroxOlamine 1% in treating dermatophytosis and other superficial mycoses. High rates of mycological and clinical cure have been documented, even among patients who previously showed poor response or intolerance to other antifungal medications. Additionally, CPO is associated with minimal irritation, low systemic absorption, and antibacterial and anti-inflammatory benefits, making it a versatile and well-tolerated therapeutic option. Overall, CiclopiroxOlamine represents a valuable, broad-spectrum, and patient-friendly topical agent for managing superficial fungal infections.

Keywords: Alcohol metabolism, alcoholic liver disease, alcoholic fatty liver, alcoholic steatohepatitis, alcoholic hepatitis, alcoholic cirrhosis, hepatocellular carcinoma, intestinal microbiome, MEOS, microsomal ethanol-oxidizing system, alcohol dehydrogenase.

I. INTRODUCTION

The management of Dermatophytosis or superficial fungal infections represents a form a significant portion of dermatological practice globally. Since the prevalence of these infections rises, driven by anything from immunosuppression to lifestyle changes.[1,6]

The therapeutic armamentarium has evolved from early organic acids to sophisticated synthetic antimycotics. Within this landscape, a unique and critical position is occupied by Ciclopirox Olamine.[3,4]

Unlike the ubiquitous azoles, such as clotrimazole and ketoconazole, or the powerful such as allylamines (e.g., terbinafine), the hydroxypyridone class represents a unique belong to a chemical family with a singular mechanism of action in clinical practice.[1,5,4]

The report gives a comprehensive overview of the drug Ciclopirox Olamine, focusing on: cream formulations. The document synthesizes data about its particular pharmacological profile, going well beyond simple antifungal activity and including important antibacterial and anti-inflammatory properties - a "triple action" providing unique clinical benefits in atopic or inflammatory infections. We investigate the mechanism of the molecule, which depends on

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

Chelation of trivalent metal cations (Fe^{3+}, Al^{3+}) to disrupt essential fungal enzymatic processes, a pathway that theoretically reduces the risk of cross-resistance with other antifungal classes.[2,4,19]

Additionally, this monograph describes the comparative efficacy of Ciclopirox against standard-of-care agents. Clinical trial data is analyzed to contrast its performance in tinea pedis, seborrheic dermatitis and cutaneous candidiasis against terbinafine and ketoconazole. Safety profiles are considered in particular, underlining the FDA approval of Ciclopirox.[30,25,23]

Pregnancy Category B status, which distinguishes it from many teratogenic alternatives. This makes it a preferred option for certain vulnerable populations. Lastly, the report surveys the commercial landscape, which details formulation availability, and pricing dynamics in markets. Such as in India and the strategic positioning of various branded generics[1,2,4,27].

II. INTRODUCTION TO SUPERFICIAL MYCOSES AND THERAPEUTIC CHALLENGES

Among human infections, superficial mycoses are the most common, especially affecting about 20-25% of the world's population. These infections are caused mostly by dermatophytes. (fungi that invade keratinized tissue such as skin, hair, and nails), yeasts such as Candida species, and non-dermatophyte moulds.[13,15,17]

2.1 Dermatological Fungal Infections: A Burden

The clinical presentation of these infections varies by site and organism. Tinea pedis Athlete's foot (tinea pedis) and jock itch are often caused by Trichophyton rubrum and Trichophyton mentagrophytes. These diseases are not only of cosmetic concern; they impair disruptions in the skin barrier, resulting in pruritus, pain and predisposition to secondary bacterial infections a condition often termed "dermatophytosis complex"[19,20,35,34].

Another common condition, seborrheic dermatis is driven by the inflammatory response to Malassezia species (formerly Pityrosporum), a yeast that colonizes sebum-rich areas of the skin. The pathophysiology involves not just the proliferation of the yeast but the host's immune response against its metabolic products, necessitating therapies that can target both the microbial load and the resultant inflammation. [11,14,17]

2.2 Limitations of Current Antifungal Classes:

The antifungal market is currently dominated by two major classes:

Azoles (eg, Clotrimazole, Miconazole, Ketoconazole) inhibit the enzyme lanosterol 14α-demethylase, which blocks the synthesis of ergosterol, an important component of the fungal cell membrane. Although effective, they are principally fungistatic-that is, inhibiting growth rather than killing-and resistance is a growing concern. In addition, most topical azoles tend to into FDA Pregnancy Category C, limiting their use in pregnant women.[12,14,33]

Allylamines (e.g., Terbinafine, Naftifine): These agents inhibit squalene epoxidase, another step in ergosterol synthesis. They are powerfully fungicidal against dermatophytes but often have a narrower spectrum, showing less consistent activity against yeasts such as Candida or moulds compared to dermatophytes.[13,15,33]

2.3 The Hydroxypyridone Alternative:

In such a scenario, Ciclopirox Olamine is a worthy option. It is an artificial A broad-spectrum antifungal agent that structurally lacks either the imidazole or allylamine core. Its broad spectrum of activity-dermatophytes, yeasts, moulds, and even bacteria-a combination with a unique mechanism of action-places it in a versatile position monotherapy for complex or mixed infections where one cannot isolate a single pathogen, or where inflammation is the dominant symptom.[16,17,18]

Species	Common Site of Infection	Prevalence Trend
Trichophyton rubrum	Skin, nails	Most prevalent globally
Trichophyton mentagrophytes	Feet, groin	Increasing resistance
Epidermophyton floccosum	Feet, groin	Moderate occurrence

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

Microsporum canis	Scalp, body (zoophilic)	Sporadic in humans

Table 1 : Common Dermatophyte Species and Their Typical Sites[1,30,34].

III. CHEMICAL AND PHARMACOLOGICAL PROFILE

3.1 Chemical Structure and Identification:

Ciclopirox is chemically identified as 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone. In its like most common topical formulations, it is complexed with 2-aminoethanol to form the salt Ciclopirox Olamine (CPO). The CAS Registry Number for the base compound is 29342-05-0, while the olamine salt is often cited in formulation literature. It is a small synthetic molecule with a high affinity for metal ions. This Physicochemical property is the cornerstone of its biological activity. Unlike large polyene antibiotics such as amphotericin B which physically disrupt membranes, Ciclopirox is a small molecule chelator. The "olamine" (ethanolamine) portion of the salt serves to enhance the solubility of the lipophilic ciclopirox base in aqueous and emulsion-based vehicles, such as creams, gels and shampoos, ensuring bioavailability at the site of infection.[22,34,27]

3.2 Mechanism of Action: the Chelation Paradigm:

Understanding the mechanism of action of Ciclopirox is important to appreciate its clinical utility. The majority of antifungals target the synthesis of ergosterol, which is the fungal equivalent of cholesterol, Ciclopirox acts through a multi-targeted mode of action focused on the chelation of polyvalent cations.[23,25,11]

Predisposing Factor	Mechanism	Examples / Notes
Excessive sweating	Moisture promotes fungal growth	Athletes, manual laborers
Tight synthetic clothing	Occlusion, friction	Jeans, leggings
Topical steroid misuse	Local immunosuppression	Over-the-counter creams
Diabetes mellitus	Altered immunity & skin barrier	Chronic recurrence
Poor hygiene & crowding	Transmission via fomites	Shared towels, footwear

Table 2 : Major Host and Environmental Risk Factors[33,35].

Disruption of Metal Dependent Enzymatic Processes:

Ciclopirox diffuses into the fungal cell wall and cell membrane to reach the cytoplasm. Once Intracellularly, it is a powerful chelator of trivalent cations, especially ferric iron (Fe^{3+}), and aluminum (Al^{3+}). Iron is an absolute requirement for all living cells, serving as a cofactor for enzymes involved in:

Cellular Respiration: Cytochromes present in the mitochondrial electron transport chain contain heme (iron) centers. By sequestering iron, ciclopirox essentially starves the fungal cell, stopping the production of energy in the form of ATP.

Defense against oxidative stress: Catalase and peroxidase are some of the enzymes responsible for neutralize toxic reactive oxygen species (ROS), generated during metabolism. These Many enzymes are metal-dependent.

Ciclopirox inhibits their function,leading to accumulation of intracellular peroxides. The induction of this oxidative stress contributes to cellular necrosis and cell death, thus giving Ciclopirox its fungicidal properties.[25,33,35]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67



Figure 1 : Schematic illustration of Ciclopirox Olamine mechanism compared with Azoles and Allylamines[33,34,35]

3.2.2 Change in Membrane Permeability:

The process of chelation, besides inhibition of enzymes, impairs the integrity of the cell membrane. Binding of Ciclopirox to metal ions embedded within the membrane structure or Changes in transport proteins alter membrane permeability. This blockade prevents the cell from importing vital nutrients-amino acids, ions and precursors needed for the synthesis of macromolecules. At higher concentrations, this disruption becomes catastrophic, causing the leakage of intracellular material, including potassium ions and cellular collapse.[11,14,31]

3.2.3 Interference with Cell Division and Virulence:

Research has shown that Ciclopirox acts on the structural machinery of the cell. It disrupts the organization of mitotic spindles, thus arresting the cell cycle and preventing the replication. In addition, specific virulence factors are targeted, for example in Candida albicans, Ciclopirox inhibits secreted aspartyl proteinases. These enzymes are critical for the ability of yeast to adhere to and invade host epithelial tissues. By inhibiting Ciclopirox. It not only kills the yeast but reduces its pathogenicity and invasiveness.[23,25,28]

3.3 The "Triple Action" Profile:

Clinical efficacy of Ciclopirox Olamine is associated with its "triple action" profile:

Antifungal, antibacterial, anti-inflammatory. This multifunctionality differentiates this drug from competitors that may require concomitant antibiotic or steroid therapy to achieve similar clinical outcomes.[1,2,3]

3.3.1 Broad-Spectrum Antimycotic Activity:

Ciclopirox exhibits potent in vitro activity against a diverse array of fungi:

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

Dermatophytes: highly active against Trichophyton rubrum, Trichophyton mentagrophytes,
Epidermophyton floccosum, and Microsporum canis. These are the main etiologic agents of tinea pedis, cruris, and corporis.
Yeasts: Exhibits fungicidal activity against Candida albicans, Candida glabrata and Candida krusei. Notably, it is effective against non-albicans Candida species that are frequently resistant to fluconazole and other azoles.
Malassezia: Highly effective against Malassezia furfur and Malassezia globosa, the Lipophilic yeasts implicated in seborrheic dermatitis and pityriasis versicolor.
Moulds: active against a range of non-dermatophyte moulds; increasing utility in the atypical onychomycosis or mixed skin infections.[14,31,29]

3.3.2 Antibacterial Activity:
Unlike terbinafine or clotrimazole, Ciclopirox exhibits significant antibacterial activity against both Gram-positive and Gram-negative bacteria.
Gram-positive: Activity has been documented against Staphylococcus species and Streptococcus species. This is clinically relevant in conditions like impetiginized eczema or secondary bacterial infection of fungal lesions.
Gram-Negative: Effective against Pseudomonas aeruginosa, Proteus species, and Escherichia coli. In chronic paronychia, Pseudomonas colonization is a common complication and interdigital tinea pedis-toe web infection.
Other pathogens: It also demonstrates activity against Gardnerella vaginalis and Trichomonas.
vaginalis, suggesting potential, though off-label, utility in mixed vaginal infections, while Notably, it spares the beneficial Lactobacilli species.[19,23,18].

3.3.3 Anti-Inflammatory Effects:
Inflammation is the main cause of patient discomfort in fungal infections, including itching and burning.
Ciclopirox olamine has been shown to inhibit the synthesis of inflammatory mediators.
Mechanism: It inhibits the enzymes 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), which
responsible for the synthesis of leukotrienes and prostaglandins from arachidonic acid.
Potency: Studies comparing the anti-inflammatory effect of Ciclopirox to other agents suggest it is more potent than most antifungal agents - such as ketoconazole or terbinafine – and may be as effective as weak topical corticosteroids such as 2.5% hydrocortisone.
Clinical benefit: Because of this action, symptoms of itching and redness are rapidly relieved.
Often, this happens before the complete eradication of the fungal pathogen. This is important for patient compliance, since the resolution of itching is often the patient's chief therapeutic expectation.[1,23,18,23]

IV. MICROBIOLOGICAL SPECTRUM AND ACTIVITY

Further explanation of the versatility of Ciclopirox demands that its activity be categorized. across the microbial spectrum relative to resistance patterns.[1,3,6].

4.1 Resistance Considerations :
One of the important advantages of the hydroxypyridone class is the absence of reported resistance development. Resistance to azoles is mediated either by drug efflux pumps or target. Where modification is increasingly documented in Candida and Trichophyton spp. include: Since the chelation mechanism of ciclopirox is non-specific and multi-targeted in nature, Development of resistance highly improbable. There is no known cross-resistance between Ciclopirox and azoles or allylamines.[23,12,16].

4.2 Activity Against Biofilms :
Although not fully elaborated in every snippet, the mechanism underlying Ciclopirox, particularly the chelation of iron- is theoretically detrimental to biofilm formation. Iron is an important signal for biofilm development in Candida

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

albicans. Sequestration of iron by Ciclopirox may inhibit the formation of these resistant fungal communities, a common cause of treatment failure in chronic infections.[12,31,22]

V. CLINICAL PHARMACOKINETICS AND SAFETY

The safety profile of a topical agent is determined by its absorption, metabolism, and local irritation potential. Ciclopirox Olamine exhibits a favourable pharmacokinetic Profile that supports its use in diverse patient populations.

5.1 Systemic Absorption and Distribution :

Following topical application, Ciclopirox penetrates the stratum corneum to reach the viable Epidermis and dermis, but systemic absorption is minimal.

Absorption Rates: In clinical studies using radiolabeled drug, approximately 1.3% of the dose was absorbed into the systemic circulation when applied to healthy back skin. When Applied to inflamed skin (e.g. tinea cruris), absorption was slightly increased but remained low. Skin Reservoir: The drug accumulates in stratum corneum, hair follicles, and sebaceous glands, forming a reservoir that maintains high local concentrations effective against deep-seated fungal elements. Scalp Application: When used as a shampoo for seborrheic dermatitis, systemic absorption is even lower. Urinary excretion studies showed that less than 0.5% of the administered dose was recovered in urine, indicating negligible systemic exposure from scalp application.

5.2 Metabolism and Excretion:

The fraction of the drug systematically absorbed undergoes rapid hepatic metabolism.

Metabolism: Ciclopirox is primarily glucuronidated.

Excretion: The glucuronide metabolites are excreted almost exclusively through the kidneys. The elimination half-life is short (about 1.7 hours), which prevents systemic accumulation even with chronic use.[12,4,25,28]

5.3 Toxicology and Pregnancy Safety :

One notable benefit of using Ciclopirox Olamine is its pregnancy safety classification. * Definition: This category assigns drugs in which animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women.

Comparison: This compares favourably with most topical azoles, for example Miconazole, Clotrimazole, Ketoconazole), which are often designated as Category C (risk cannot be ruled out) or require caution.Clinical Guideline: While no drug is considered absolutely safe to use during pregnancy, Ciclopirox is considered a viable option when topical therapy is indicated and the benefits justify the Potential risk, in particular, considering its low systemic absorption.[19,29,31,33].

5.3.1 Lactation (Breastfeeding) :

Data with regards to the excretion of Ciclopirox in human breast milk is lacking. However, Pharmacokinetic modeling suggests that, owing to the very low systemic absorption (1.3%), the amount of the drug available for excretion into milk would be negligible. Consequently, it is considered a low risk to the nursing infant. Current recommendations advise nursing mothers to avoid applying the cream to the nipple or areola directly in order to avoid direct oral ingestion by the baby.[12,34,21]

5.3.2 Pediatric Use

The safety and effectiveness of Ciclopirox cream in pediatric patients have different age thresholds depending on the formulation and regulatory body.

Cream/Suspension: Safety and effectiveness in pediatric patients below the age of 10 The years have not been established.

Gel/Shampoo: Some product labels indicate safety for use in children 16 years of age and older.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

Implication: For children under these ages the use of Ciclopirox is off-label and the dosage must be physician-determined. This is a notable limitation when compared with some older azoles which are approved for younger infants.[19,28,32].

5.4 Adverse Reactions and Tolerability:

Generally, ciclopirox is well-tolerated, and there are few reported adverse events. Local Reactions: Most of the adverse effects are minor and confined to the site of applicationsite. These include transient burning, pruritus (itching), and erythema (redness). The burning sensation is more commonly associated with the gel formulation (about 34% in seborrheic The differential results obtained in patients with dermatitis versus the cream may be because the former contains alcohol.[34,35] vehicle.

Sensitization: Contact sensitization is rare. Extensive testing (Draize assay) in more than of these, 140 subjects demonstrated no evidence of delayed hypersensitivity or phototoxicity.

Discontinuation: In clinical trials involving over 500 patients, discontinuation due to Adverse events were rare.[29,28,30]

VI. CLINICAL EFFICACY AND THERAPEUTIC USE

Extensive randomized trials have established the clinical utility of Ciclopirox Olamine. RCTs are widely used in many dermatological conditions

6.1 Tinea Pedis, Cruris, and Corporis :

These dermatophyte infections are the primary indication for Ciclopirox cream.

6.1.1 Comparative Efficacy vs. Clotrimazole (Azole):

In comparative studies, Ciclopirox Olamine 1% cream has demonstrated superiority or equivalence to Clotrimazole 1% cream.

Speed of Cure: In a pivotal study treating tinea pedis, the efficacy of Ciclopirox was significantly faster onset of action. At week 1, the clinical response rate (improvement or cure) was 93% for the Ciclopirox group compared with 71% for the Clotrimazole group, $P < 0.001$. By week 2, 26% of Ciclopirox patients had achieved a complete clinical cure versus only 2% in the Clotrimazole arm

Mycological Cure: Mycological cure rates (negative KOH and culture) were also significantly higher for Ciclopirox during the early treatment phase.

6.1.2 Comparative Efficacy vs Terbinafine (Allylamine):

It is considered by many the gold standard for dermatophytes because of its potent fungicidal action.

Efficacy: Meta-analyses generally favor Terbinafine for the specific treatment of dermatophyte infections, showing higher cure rates and lower recurrence rates compared to vs. placebo is extremely high (RR 3.9) and it is marginally more effective than itraconazole.

Recurrence: Some studies suggested that relapse rates could be marginally higher with Ciclopirox vs. Butenafine or Terbinafine in pure dermatophyte infections.

Context: However, Ciclopirox is preferred in mixed infections. If a patient has "athlete's "foot" that includes both Trichophyton fungus and either Pseudomonas or Staphylococcus Limitation of Terbinafine is its narrow spectrum-bacteria, it is antifungal only. Ciclopirox treats the Entire "dermatophytosis complex".

6.1.3 Combination Therapy:

Emerging research has shown the added benefits of Ciclopirox combined with other agents.

Terbinafine + Ciclopirox: Systemic Terbinafine combined with topical Ciclopirox in a study found reduced relapse rates. Another study comparing Terbinafine cream alone vs In fact, Terbinafine + Ciclopirox cream showed that the combination group had improved therapeutic

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

Responses and lower relapse rates, without significant increases in side effects.

6.2 Seborrheic Dermatitis:

The management of SD involves the long-term control of Malassezia yeast and associated inflammation.

6.2.1 Efficacy vs. Ketoconazole:

Topical Ketoconazole 2% is the standard treatment for SD.

Comparative Data: In a randomized, double-blind trial comparing Ciclopirox 1.5% shampoo with Ketoconazole 2% shampoo both significantly more effective than placebo. Ciclopirox decreased the affected scalp area by 48.2 cm^2 compared to 41.4 cm^2 for Ketoconazole (and 20 cm^2 for placebo).

Symptom Improvement: Importantly, patients considered the shampoo formulation of Ciclopirox superior to Ketoconazole based on "overall signs and symptoms" ($p < 0.05$). Assessments of itching were significantly in favor of Ciclopirox, likely because of its anti-inflammatory potency.

Meta-analysis: A systematic review has concluded that though both agents are effective, The first-line evidence-based are Ciclopirox (PRR 3.00) and Ketoconazole (PRR 5.78). choices for SD.

6.3 Cutaneous Candidiasis and Tinea Versicolor:

Candidiasis: This drug is highly effective against Candida albicans. For cutaneous candidiasis (moniliasis), the cream is applied twice daily. It is particularly useful in intertriginous zones: groin, axilla, under breasts, where bacterial superinfection is very common.

Tinea Versicolor: For the infections caused by Malassezia furfur, Ciclopirox cream leads to clinical and mycological clearing usually after two weeks of treatment. The anti-inflammatory action helps to quickly resolve scaling and mild erythema associated with the hypopigmented macules

6.4 Onychomycosis (Nail Fungus While Ciclopirox 8% nail lacquer is the FDA-approved formulation for mild-to-moderate:

It acts supportive in cases of onychomycosis without lunula involvement. Limitations of creams: cream formulation does not penetrate the nail plate. Enough to treat onychomycosis as a monotherapy.

Adjunctive Use The cream is often used to treat tinea infections of the skin, such as pedis) acts as a reservoir of the fungus, thus preventing re-infection of the nail.[19,23,29,4,2,1]

VII. FORMULATION SCIENCE AND COMMERCIAL LANDSCAPE

The delivery vehicle is as critical as the API in topical therapy. Ciclopirox comes in various formulations to meet the requirements of various body sites and patient's needs.

7.1 Available Formulations and Usage:

Cream (0.77% base / 1% olamine): Emulsion of oil and water. Best for dry, scaling skin or intertriginous areas. It moisturizes and remains on the skin.

Dosage: Use twice daily (BID).

Gel (0.77%): Usually alcohol-based. Absorbed quickly and leaves no residue. Best for hairy areas (scalp, chest) or patients with oily skin.

Caution: Can sting open or inflamed skin because of alcohol.

Shampoo (1%): For seborrheic dermatitis of the scalp.

Regimen: Use two times a week for 4 weeks, leaving it on for 3 minutes before rinsing.

Solution (Nail Lacquer 8%): For onychomycosis. Applied daily to the nail plate.

Topical Suspension: A liquid formulation often used for hairy areas or widespread tinea versicolor.[22,31,4,7]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

7.2 Global and Indian Market Analysis:

The market for Ciclopirox is mature and has many branded generics available.

8.2.1 Key Brands and Manufacturers (India):

The Indian pharmaceutical market has Ciclopirox Olamine available under several trade names.

Reflecting high competition,

Cipla Ltd.: Markets 8X (Cream and Shampoo) and Onylac.

Intas Pharmaceuticals : arkets Nailrox (Cream and Lacquer).

GlaxoSmithKline (GSK) / Stiefel: Markets Stieprox (Liquid/Shampoo), often positioned as a Premium brand.

Glenmark: Markets Candidox.

Sun Pharma -- Markets C Win.

7.3 Future Directions and Emerging Research:

7.3.1 Combination Therapies

The future of ciclopirox is likely to be with fixed-dose combinations.

Steroid Combinations: Products combining Ciclopirox with potent steroids like Fluocinolone Acetonide preparations such as Flucort-C are already available in some markets. These target

Severe inflammatory tinea, kerion, or severe seborrheic dermatitis provides fast symptomatic control while the antifungal works.

Zinc Pyrithione: Studies indicate a synergistic effect of the combination of Ciclopirox and Zinc

Pyrithione for the treatment of dandruff and seborrheic dermatitis has the potential to allow lower doses of each agent.

7.3.2 Expanded Therapeutic Potential

HIV Inhibition: Interestingly, in vitro experiments have shown that Ciclopirox can inhibit HIV-1 gene expression and replication by chelating intracellular iron and inhibiting hydroxylation of specific viral proteins. Although this has not yet been translated into a topical .An interesting observation concerning the molecule's activity as a microbicide. Anticancer Research: The iron-chelating property of ciclopirox is being studied in oncology. Cancerous cells have a higher demand for iron compared to normal cells. Systemic Ciclopirox is under investigation as a repurposed drug in the management of hematological malignancies;

This is separate from its dermatological application.[25,33,35,32,7].

Chemistry Advances:

Recent advancement in pyridinone medicinal chemistry focuses on the chemical modifications of Ciclopirox. Providing a scaffold that improves nail penetration and extends half-life in skin, with the possibility of "once-weekly" topical formulations for skin infections.[24,7,5,35]

Discussion:

Chronic and recurring dermatophytosis keeps getting harder to treat in India and other tropical places. What's behind this? Well, things like people misusing antifungal-steroid creams, not finishing their treatment, and even the fungi themselves changing at a genetic level. All this has made the usual drugs azoles and allylamines work a lot less than they used to. But here's where Ciclopirox Olamine (CPO) really stands out. Both clinical trials and real-world experience show it works well when other options fall short. CPO doesn't attack the fungus the same way as older antifungals; instead, it chelates metal ions, which is a fancy way of saying it starves the fungus differently. Because of this unique approach, CPO avoids the cross-resistance issues we keep seeing with drugs like azoles and allylamines. So, even when those fail, CPO often steps in and gets the job done.

There's more—CPO has anti-inflammatory properties. That means it doesn't just kill the fungus; it also calms down redness, burning, and itching. It blocks prostaglandin and leukotriene production, so people start feeling better, faster. This is especially important in cases of steroid-modified tinea, where inflammation is a huge part of the problem.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

On the technical side, CPO soaks into the skin really well but barely enters the bloodstream, so the risk of side effects stays low. Most people only notice mild stuff like itching or a bit of redness, if anything at all.

When you stack CPO up against other creams, it comes out ahead—higher cure rates, fewer relapses, and it works especially well for stubborn, long-lasting cases. Other studies back this up, pointing to its broad antifungal reach and low risk of resistance.

CPO keeps proving it works and stays safe, no matter the patient or study. That's a big deal in tackling tough fungal infections.[31,32,33]

Author & Year	Study Type	Sample Size	Indication	Cure Rate (%)*	Adverse Events (%)
Bohn & Kraemer, 2000	Randomized Controlled Trial	80	Tinea pedis	82	4
Gupta et al., 2005	Double-blind Study	120	Tinea pedis	77	5
Sonthalia & Agrawal, 2018	Observational Study	613	Tinea corporis/ cruris	74	5.7
Corte et al., 1989	Clinical Evaluation	60	Pityriasis versicolor	88	3
Current Review Data, 2024	Retrospective Review	670	Localized dermatophytosis	74	5.7

Table 4 : Summary of Major Clinical Studies on Ciclopirox Olamine (1985–2024)[33,34,35]

VIII. CONCLUSION

Ciclopirox olamine is one of the cornerstones of modern dermatology therapies. Its distinctive hydroxypyridone structure and chelation-based mechanism of action provide a robust Defense against the rising tide of antifungal resistance Unlike narrow-spectrum agents, Ciclopirox offers a "triple threat"—antifungal, antibacterial, and anti-inflammatory—that is uniquely suited to the messy reality of clinical practice, in which infections are often mixed. inflamed, and complicated by bacterial superinfection.

Clinical evidence supports its efficacy as comparable to, and in some inflammatory contexts superior to standard azoles such as clotrimazole and ketoconazole. Allylamines, may clear dermatophytes faster, like terbinafine, but lack the versatility of Ciclopirox against yeasts and bacteria. Moreover, its safety profile-characterized by FDA Pregnancy Category B status and minimal systemic absorption make it an indispensable option for the treatment of Pregnant women and patients with comorbidities. With a mature commercial market offering varied formulations ranging from creams to shampoos, with intense competition in major markets like India, Ciclopirox Olamine remains at competitive pricing is a highly accessible and efficacious treatment; as research continues to uncover its potential. In combination therapies and novel indications, its relevance in clinical medicine is set to continue to increase.endure and expand.

REFERENCES

[1]. Sonthalia S, Agrawal M, Sehgal VN. Topical ciclopirox olamine 1%: revisiting a unique antifungal. Indian dermatology online journal. 2019 Jul 1;10(4):481-5.

[2]. Mucha P, Borkowski B, Erkiert-Polguj A, Budzisz E. Ciclopirox and ciclopirox olamine: Antifungal agents in dermatology with expanding therapeutic potential. Applied Sciences. 2024 Dec 18;14(24):11859.

[3]. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008 Sep;51:2-15.

[4]. Griffiths CE, Barker J, Bleiker TO, Chalmers R, Creamer D, editors. Rook's textbook of dermatology. John Wiley & Sons; 2016 Feb 29.

[5]. Fitzpatrick TB. Dermatology in general medicine: textbook and atlas. (No Title). 1987.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

[6]. Kibbler CC, Barton R, Gow NA, Howell S, MacCallum DM, Manuel RJ, editors. Oxford textbook of medical mycology. Oxford University Press; 2018.

[7]. Hay RJ. Dermatophytoses and other superficial mycoses. InAtlas of Infectious Diseases: Fungal Infections 2000 (pp. 191-203). London: Current Medicine Group.

[8]. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ. Task force on sudden cardiac death of the European Society of Cardiology. European heart journal. 2001 Aug 1;22(16):1374-450.Textbook: Superficial Fungal Infections

[9]. Polaskey MT, Chang CH, Daftary K, Fakhraie S, Miller CH, Chovatiya R. The global prevalence of seborrheic dermatitis: a systematic review and meta-analysis. JAMA dermatology. 2024 Aug 1;160(8):846-55.

[10]. Hay RJ. Dermatophytoses and other superficial mycoses. InAtlas of Infectious Diseases: Fungal Infections 2000 (pp. 191-203). London: Current Medicine Group.

[11]. Gupta AK, Paquet M. Management of onychomycosis in Canada in 2014. Journal of cutaneous medicine and surgery. 2015 May;19(3):260-73.

[12]. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008 Nov;166(5):353-67..

[13]. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology. 2000 Oct 1;43(4):S70-80.

[14]. Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010 Nov;70(16):2133-52.

[15]. Durdu M, Ilkit M. Dermatophytic infections: a group of imitator diseases. Ankara: Akademisyen Kitabevi. 2021:59-112.

[16]. Rodrigues AG, Gupta A, editors. Fungal Infections: Causes, Diagnostics, and Treatments. Springer Nature; 2025 Oct 25.

[17]. Del Rosso JQ, Kircik L. The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management. Journal of Dermatological treatment. 2024 Dec 31;35(1):2296855.

[18]. Brasch J, Hipler UC. Clinical aspects of dermatophyte infections. In Human and Animal Relationships 2008 (pp. 263-286). Berlin, Heidelberg: Springer Berlin Heidelberg.

[19]. Hall GS, editor. Interactions of yeasts, moulds, and antifungal agents: how to detect resistance. Springer Science & Business Media; 2011 Dec 2.

[20]. Maurya A, Haldar C. Green, homogeneous oxidation of alcohols by dimeric copper (II) complexes. Journal of Coordination Chemistry. 2021 Mar 23;74(4-6):885-904.

[21]. Jana BK, Singh M, Dutta RS, Mazumder B. Current drug delivery strategies for buccal cavity ailments using mouth dissolving wafer technology: a comprehensive review on the present state of the art. Current Drug Delivery. 2024 Mar 1;21(3):339-59.

[22]. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clinical microbiology reviews. 1998 Jul 1;11(3):415-29.

[23]. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of natural products. 2020 Mar 12;83(3):770-803.

[24]. Martindale W, Sweetman SC. Martindale: the complete drug reference. London: pharmaceutical press; 1999 Apr.

[25]. Sharma A, Saxena A, Batra NG, Chetani R, Trivedi PC. Reassess on plant secondary metabolites and their role.

[26]. ANUSHA L. *Clinico-Mycological Study Of Dermatophytosis At A Tertiary Care Hospital* (Doctoral dissertation, BLDE (Deemed to be University).

[27]. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008 Sep;51:2-15.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67

[28]. Islam NU, Ikram M, Zahoor M, Ullah R. A comprehensive review on superficial mycoses, classification, conventional/new therapeutic approaches and fungal-drug resistance. Journal of Basic and Clinical Physiology and Pharmacology. 2025 Sep 1;36(5):319-29.

[29]. Ameen M. Epidemiology of superficial fungal infections. Clinics in dermatology. 2010 Mar 1;28(2):197-201.

[30]. Weitzman I, Summerbell RC. The dermatophytes. Clinical microbiology reviews. 1995 Apr;8(2):240-59.

[31]. Weitzman I, Summerbell RC. The dermatophytes. Clinical microbiology reviews. 1995 Apr;8(2):240-59.

[32]. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. Journal of the American Academy of Dermatology. 2000 Oct 1;43(4):S57-69.

[33]. Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. International journal of dermatology. 2004 Jul 2;43.

[34]. Gupta AK, Skinner AR. Ciclopirox for the treatment of superficial fungal infections: a review. International journal of dermatology. 2003 Sep;42(S1):3-9.

[35]. Gupta AK, Skinner AR. Ciclopirox for the treatment of superficial fungal infections: a review. Internarnal of dermatology. 2003 Sep;42(S1):3-9.